Sun Pharma’s $11.75 billion Organon deal could boost its global scale and biosimilars reach, but investors are closely watching debt levels, execution risks and long-term returns
Source :- Companies Read More
August 21, 2026
Sun Pharma’s $11.75 bn Organon bet: Global pharma leap or balance risk?
- No Comments
- 6 Min Read
Share it :
Get free tips and resources right in your inbox, along with 10,000+ others
Categories
Latest Post
August 21, 2026
August 21, 2026
August 21, 2026
